Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe why insulin fails to control fat in Upper-Body obesity

NCT ID NCT03866408

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study at Mayo Clinic is looking at why insulin doesn't properly control fat breakdown in people with upper-body obesity. Researchers will test the diabetes drug pioglitazone and weight loss programs in 64 adults to see how fat cells respond. The goal is to understand the underlying biology, not to find an immediate cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pioglitazone
What this could lead to
If successful, this study could reveal why insulin fails to control fat breakdown in upper-body obesity, pointing toward better treatments for insulin resistance.
What could go wrong
This is a very early, small study focused on understanding biological mechanisms, not on proving a treatment works. Results may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.